Apollomics announces presentation of vebreltinib data at the 2023 iaslc north america conference on lung cancer (naclc)

Foster city, calif., nov. 28, 2023 (globe newswire) -- apollomics inc. (nasdaq: aplm ) (the “company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced a poster presentation of clinical results for vebreltinib in the treatment of nsclc with met exon 14 skipping mutation with or without concurrent met amplification at the 2023 iaslc north america conference on lung cancer (naclc), being held on december 1 through 3, 2023 in chicago, illinois.
APLM Ratings Summary
APLM Quant Ranking